Compare · PRDS vs SQZ
PRDS vs SQZ
Side-by-side comparison of Pardes Biosciences Inc. (PRDS) and SQZ Biotechnologies Company (SQZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRDS and SQZ operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- PRDS has more recent analyst coverage (3 ratings vs 0 for SQZ).
- Company
- Pardes Biosciences Inc.
- SQZ Biotechnologies Company
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 3
- 0
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company
Latest SQZ
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)
- SEC Form DEFM14A filed by SQZ Biotechnologies Company
- SEC Form PREM14A filed by SQZ Biotechnologies Company
- SEC Form 15-12G filed by SQZ Biotechnologies Company
- SQZ Biotechnologies Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form EFFECT filed by SQZ Biotechnologies Company
- SEC Form POS AM filed by SQZ Biotechnologies Company
- SEC Form S-8 POS filed by SQZ Biotechnologies Company
- SEC Form 10-Q filed by SQZ Biotechnologies Company